GT BioPharma to Host Management Update Conference Call

– Tuesday, November 30 at 4:30 p.m. EST

BEVERLY HILLS, Calif., November 24, 2021 / PRNewswire / – GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on the development of innovative therapies based on the natural killer cell activator (NK ) Company’s exclusive, the TriKE® platform, today announced that Michael breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will host a management update conference call on Tuesday, November 30e To 4:30 p.m. Eastern Time.

GT Biopharma logo (PRNewsfoto / GT Biopharma, Inc.)

To join the live webcast of the call and view the accompanying slide presentation, please use this link:
https://viavid.webcasts.com/starthere.jsp?ei=1516135&tp_key=68a3021ba2

Those who wish to connect by phone for the audio-only portion of the event can do so at:

Toll-free number for participants: 1-877-407-9039
INTERNATIONAL DIAL-IN PARTICIPANT: 1-201-689-8470
CONFERENCE ID: 13725380

An archived replay of the webcast will be available on the Company’s website by visiting:
https://www.gtbiopharma.com/news-media/presentations

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutics based on our proprietary TriKE® NK cell engagement platform. Our TriKE® is designed to harness and enhance the cancer killing capabilities of natural killer cells in a patient’s immune system. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota continue the development and commercialization of therapies using TriKE® Technology. For more information, please visit gtbiopharma.com.

Forward-looking statements

The management update conference call will contain certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding our clinical direction and our current and proposed trials. Words and phrases reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes”, “hopes”, “intends”, “esteem”, “s ‘expects to’, ‘plans’, ‘plans’, ‘anticipates’ and their variations, or the use of the future, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not guarantees of performance, and actual results could differ materially from those contained or expressed by such statements. When evaluating all of these statements, we invite you to specifically consider the various risk factors identified in our annual report on Form 10-K for the fiscal year ended. December 31, 2020, our subsequent current reports on Form 8-K, our quarterly report on Form 10-Q for the quarter ended September 30, 2021, and our other documents filed with the Securities and Exchange Commission, each of which could cause actual results to differ materially from those shown in our forward-looking statements.

Our forward-looking statements reflect our current views regarding future events and are based on current financial, economic, scientific and competitive data and information available on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our continued ability to raise additional capital to fund our operations, (ii) our ability to complete planned clinical trials, or meet FDA requirements for safety and efficacy, (iii) our ability to identify patients for enrollment in our clinical trials in a timely manner , (iv) our ability to achieve marketable product approval, (v) the design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of adverse clinical trial results, (vii) the market and commercialization of any product that is approved, (viii) the existence or development of treatments that are considered by healthcare professionals or patients s as superior to our products, (ix) regulatory initiatives, compliance with government regulations and regulatory approval process and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or if the underlying assumptions prove to be incorrect, actual results could differ materially and adversely from those anticipated, believed, estimated or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in the Management Update Call will be subject to the safe harbor protection of federal securities laws in accordance with Section 27A of the Securities Act, to the extent applicable. Except as required by law, we assume no responsibility to update these forward-looking statements to reflect events or circumstances that occur after the date of the management update call. In addition, we assume no responsibility for keeping you informed of the occurrence of unforeseen events that could cause actual results to differ from those expressed or implied by such forward-looking statements.

TriKE is a registered trademark owned by GT Biopharma, Inc.

Investor Relations Contacts:

GT Biopharma-Investor Relations Consultant
David Castaneda
[email protected]
414-351-9758

LifeSci Advisors
Corey davis, Ph.D.
[email protected]
212-915-2577

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-biopharma-to-host-a-management-update-conference-call-301431776.html

SOURCE GT Biopharma, Inc.


Source link

Back To Top